Literature DB >> 505340

Pulmonary hypertension accompanying ventricular septal defect and patent ductus arteriosus. Management in infancy and early childhood.

J M Reid, E N Coleman, J G Stevenson.   

Abstract

Forty-one infants and children with the combination of patent ductus arteriosus (PDA) and ventricular septal defect (VSD) were encountered over 20 years. Twenty-four presented in infancy with congestive cardiac failure. Pulmonary hypertension was present in 32, the cause in 19 being increased pulmonary blood flow. Increased pulmonary vascular resistance (PVR) was detected in 13 (indicated by a pulmonary to systemic resistance ratio (Rp : RS) greater than 0.24:1 and PVR greater than 4 units). Thus 22% had a pulmonary artery systolic pressure less than 30 mmHg and 68% had a pulmonary vascular resistance below four units, indicating an unusually mild form of the combined condition in these patients. Surgical management is discussed, and in particular the question of simultaneous closure of the defects during infancy. Cardiac failure, resistant to drug treatment, and increased PVR are indications of operation. The PDA should be closed and only if there is no substantial fall in pulmonary artery pressure is the VSD repaired.

Entities:  

Mesh:

Year:  1979        PMID: 505340      PMCID: PMC471096          DOI: 10.1136/thx.34.4.454

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  14 in total

1.  SURGICAL TREATMENT OF VENTRICULAR SEPTAL DEFECT ASSOCIATED WITH PULMONARY HYPERTENSION.

Authors:  G L HALLMAN; D A COOLEY; R R WOLFE; D G MCNAMARA
Journal:  J Thorac Cardiovasc Surg       Date:  1964-10       Impact factor: 5.209

2.  HIGH-PRESSURE VENTRICULAR SEPTAL DEFECTS.

Authors:  C W LILLEHEI; M J LEVY; P ADAMS; R C ANDERSON
Journal:  JAMA       Date:  1964-06-15       Impact factor: 56.272

3.  The natural history of ventricular septal defects in infancy and childhood, based on serial cardiac catheterization studies.

Authors:  J LYNFIELD; B M GASUL; R ARCILLA; L L LUAN
Journal:  Am J Med       Date:  1961-03       Impact factor: 4.965

4.  The pathology of hypertensive pulmonary vascular disease; a description of six grades of structural changes in the pulmonary arteries with special reference to congenital cardiac septal defects.

Authors:  D HEATH; J E EDWARDS
Journal:  Circulation       Date:  1958-10       Impact factor: 29.690

5.  The treatment of certain congenital malformations of the heart by the creation of pulmonic stenosis to reduce pulmonary hypertension and excessive pulmonary blood flow; a preliminary report.

Authors:  W H MULLER; J F DANIMANN
Journal:  Surg Gynecol Obstet       Date:  1952-08

6.  Ventricular septal defect repair after pulmonary artery banding.

Authors:  E N Coleman; J M Reid; R S Barclay; J G Stevenson
Journal:  Br Heart J       Date:  1972-02

7.  Results of repair of ventricular septal defect.

Authors:  T B Cartmill; J W DuShane; D C McGoon; J W Kirklin
Journal:  J Thorac Cardiovasc Surg       Date:  1966-10       Impact factor: 5.209

8.  Two-stage surgical treatment of ventricular septal defect: results of pulmonary artery banding in infants and subsequent open-heart repair.

Authors:  G L Hallman; D A Cooley; R D Bloodwell
Journal:  J Thorac Cardiovasc Surg       Date:  1966-10       Impact factor: 5.209

9.  Multiple and single ventricular septal defect. A clinical and haemodynamic comparison.

Authors:  K M Fox; R G Patel; G R Graham; J F Taylor; J Stark; M R De Leval; F J Macartney
Journal:  Br Heart J       Date:  1978-02

10.  Functional status of patients with large ventricular septal defect and pulmonary vascular disease 6 to 16 years after surgical closure of their defect in childhood.

Authors:  K A Hallidie-Smith; R S Wilson; A Hart; E Zeidifard
Journal:  Br Heart J       Date:  1977-10
View more
  1 in total

1.  Pulmonary hypertension accompanying ventricular septal defect and patent ductus arteriosus: management in infancy and early childhood.

Authors:  F J Macartney; J Stark
Journal:  Thorax       Date:  1980-04       Impact factor: 9.139

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.